{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:31:49Z","timestamp":1793028709011,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ijbiomac.2025.144497","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T16:03:08Z","timestamp":1747843388000},"page":"144497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"P2","title":["Chitosan-coated nanostructured lipid carriers of amantadine for nose-to-brain delivery: formulation optimization, in vitro-ex vivo characterization, and in vivo anti-parkinsonism assessment"],"prefix":"10.1016","volume":"316","author":[{"given":"Archita","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Hafeez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nargis","family":"Ara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.144497_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122232","article-title":"Formulation of intranasal surface engineered nanostructured lipid carriers of rotigotine: full factorial design optimization, in vitro characterization, and pharmacokinetic evaluation","volume":"627","author":"Zafar","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0010","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-024-03216-2","article-title":"Effect of mGluR2 and mGluR2\/3 activators on parkinsonism in the MPTP-lesioned non-human primate","author":"Frouni","year":"2024","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.144497_bb0015","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10876-023-02531-7","article-title":"Donepezil and embelin loaded nanostructured lipid carriers for direct brain delivery as an intervention for Alzheimer\u2019s disease: formulation design, optimization and evaluation","volume":"35","author":"Ali","year":"2024","journal-title":"J. Clust. Sci."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.144497_bb0020","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s11064-024-04099-8","article-title":"Orientin modulates Nrf2-ARE, PI3K\/Akt, JNK-ERK1\/2, and TLR4\/NF-kB pathways to produce neuroprotective benefits in Parkinson\u2019s disease","volume":"49","author":"Vasudevan Sajini","year":"2024","journal-title":"Neurochem. Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.144497_bb0025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2174\/1871527322666230501232815","article-title":"Emerging nanotechnology for the treatment of Alzheimer\u2019s disease","volume":"23","author":"Singh","year":"2024","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.144497_bb0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00210-022-02201-x","article-title":"Pycnogenol ameliorates motor function and gene expressions of NF-\u0199B and Nrf2 in a 6-hydroxydopamine-induced experimental model of Parkinson\u2019s disease in male NMRI mice","volume":"395","author":"Jafari","year":"2022","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0035","first-page":"1","article-title":"Parkinson\u2019s disease: current drug therapy and unraveling the prospects of nanoparticles","volume":"58","author":"Paul","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119148","article-title":"Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson\u2019s disease","volume":"579","author":"Bhattamisra","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"22","key":"10.1016\/j.ijbiomac.2025.144497_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212263","article-title":"Sirtuins and autophagy in age-associated neurodegenerative diseases: lessons from the C. elegans model","volume":"22","author":"Naseer","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bpc.2015.04.002","article-title":"Interactions of the antiviral and antiparkinson agent amantadine with lipid membranes and human erythrocytes","volume":"202","author":"Suwalsky","year":"2015","journal-title":"Biophys. Chem."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.144497_bb0055","first-page":"198","article-title":"Revisiting amantadine as a treatment for drug-induced movement disorders","volume":"32","author":"Caroff","year":"2020","journal-title":"Ann. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.144497_bb0060","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1021\/acsomega.1c04652","article-title":"Simple and Economical Process for Producing Amantadine Hydrochloride","volume":"7","author":"Phan Thi","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0065","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00702-021-02306-2","article-title":"Amantadine: reappraisal of the timeless diamond\u2014target updates and novel therapeutic potentials","volume":"128","author":"Danysz","year":"2021","journal-title":"J. Neural Transm."},{"issue":"7709","key":"10.1016\/j.ijbiomac.2025.144497_bb0070","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0140-6736(71)91834-4","article-title":"Treatment of Parkinson\u2019s disease with amantadine and levodopa: a one-year study","volume":"297","author":"Parkes","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0075","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cherd.2022.09.049","article-title":"Development of sustainable reaction and separation processes for amantadine and amantadine hydrochloride","volume":"188","author":"Tseng","year":"2022","journal-title":"Chem. Eng. Res. Des."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.144497_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300595","article-title":"Nascent pharmacological advancement in adamantane derivatives","volume":"357","author":"Ragshaniya","year":"2024","journal-title":"Arch. Pharm."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.144497_bb0085","doi-asserted-by":"crossref","first-page":"12","DOI":"10.22159\/ajpcr.2020.v13i11.39131","article-title":"Experimental animal models of Parkinson\u2019s disease: an overview","volume":"13","author":"Imran","year":"2020","journal-title":"Asian J. Pharm. Clin. Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.144497_bb0090","first-page":"10","article-title":"An overview on the diagnosis and approaches in pharmacological management of Parkinson\u2019s disease","volume":"11","author":"Ansari","year":"2021","journal-title":"Res. Rev. J. Neurosci."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.144497_bb0095","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/02699052.2020.1723697","article-title":"Amantadine and memantine: a comprehensive review for acquired brain injury","volume":"34","author":"Ma","year":"2020","journal-title":"Brain Inj."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0100","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/TCRM.S144481","article-title":"Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson\u2019s disease","volume":"12","author":"Sharma","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0105","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1590\/1516-4446-2017-2393","article-title":"Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials","volume":"40","author":"Raupp-Barcaro","year":"2018","journal-title":"Braz. J. Psychiatry."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.144497_bb0110","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/jssc.201901298","article-title":"Amantadine hydrochloride monitoring by dried plasma spot technique: high-performance liquid chromatography\u2013tandem mass spectrometry based clinical assay","volume":"43","author":"Li","year":"2020","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0115","first-page":"1","article-title":"The efficacy of amantadine hydrochloride in the treatment of COVID-19-a single-center observation study","author":"Bodnar","year":"2021","journal-title":"Res. Sq."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.645706","article-title":"Amantadine ER (Gocovri\u00ae) significantly increases ON time without any dyskinesia: pooled analyses from pivotal trials in Parkinson\u2019s disease","volume":"12","author":"Hauser","year":"2021","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.144497_bb0125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/14737175.2019.1592677","article-title":"Extended-release amantadine for levodopa-induced dyskinesia","volume":"19","author":"Dashtipour","year":"2019","journal-title":"Expert. Rev. Neurother."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.144497_bb0130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/05704928.2011.639107","article-title":"1, 2-Naphthoquinone-4-sulphonic acid sodium salt (NQS) as an analytical reagent for the determination of pharmaceutical amine by spectrophotometry","volume":"47","author":"Elbashir","year":"2012","journal-title":"Appl. Spectrosc. Rev."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0135","article-title":"Recent progress in nanocarriers for direct nose to brain drug delivery","volume":"64","author":"Emad","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.144497_bb0140","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1166\/jbn.2016.2313","article-title":"Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson\u2019s disease","volume":"12","author":"Gartziandia","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0145","article-title":"On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles","volume":"29","author":"Formica","year":"2022","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0150","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.colsurfb.2018.11.025","article-title":"Lamotrigine encapsulated intra-nasal nanoliposome formulation for epilepsy treatment: formulation design, characterization and nasal toxicity study","volume":"174","author":"Praveen","year":"2019","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0155","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jddst.2019.04.017","article-title":"Intranasal drug delivery: novel delivery route for effective management of neurological disorders","volume":"52","author":"Patel","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0160","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijpharm.2019.05.032","article-title":"Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges","volume":"565","author":"Chatterjee","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.144497_bb0165","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1208\/s12249-012-9884-2","article-title":"Correlation between nasal membrane permeability and nasal absorption rate","volume":"14","author":"Bahadur Zhang","year":"2013","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.144497_bb0170","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","article-title":"Intranasal drug delivery: opportunities and toxicologic challenges during drug development","volume":"12","author":"Keller","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.144497_bb0175","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2174\/157341312800620331","article-title":"Formulation development of chitosan coated intra nasal ropinirole nanoemulsion for better management option of Parkinson: an in vitro ex vivo evaluation","volume":"8","author":"Mustafa","year":"2012","journal-title":"Curr. Nanosci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.144497_bb0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40005-015-0212-1","article-title":"Neuroprotective effect of ibuprofen by intranasal application of mucoadhesive nanoemulsion in MPTP induced Parkinson model","volume":"46","author":"Mandal","year":"2016","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0185","first-page":"1","article-title":"Nose to brain delivery of rotigotine loaded solid lipid nanoparticles: quality by design based optimization and characterization","volume":"63","author":"Prajapati","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.144497_bb0190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/10717544.2012.752421","article-title":"Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach","volume":"20","author":"Pardeshi","year":"2013","journal-title":"Drug Deliv."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.144497_bb0195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/10667857.2019.1674522","article-title":"Improved brain pharmacokinetics following intranasal administration of N, N, N-trimethyl chitosan tailored mucoadhesive NLCs","volume":"35","author":"Pardeshi","year":"2020","journal-title":"Mater. Technol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.144497_bb0200","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/02652048.2018.1487473","article-title":"A comparative study of stabilising effect and antioxidant activity of different antioxidants on levodopa-loaded liposomes","volume":"35","author":"Garcia Esteban","year":"2018","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0205","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2020.119046","article-title":"Facile nose-to-brain delivery of rotigotine-loaded polymer micelles thermosensitive hydrogels: in vitro characterization and in vivo behavior study","volume":"577","author":"Wang","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.144497_bb0215","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1166\/sam.2015.2289","article-title":"Development and optimization of a nanostructured lipid carrier based gel formulation of etoricoxib for topical delivery using Box-Behnken design: in vitro and ex vivo evaluation","volume":"7","author":"Hafeez","year":"2015","journal-title":"Sci. Adv. Mater."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.144497_bb0220","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00210-024-03408-w","article-title":"Leveraging nanostructured lipid carriers to enhance targeted delivery and efficacy in breast cancer therapy: a comprehensive review","volume":"398","author":"Naseem","year":"2025","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.144497_bb0225","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1208\/s12249-024-02758-1","article-title":"Nanocarrier-mediated drug delivery via inhalational route for lung Cancer therapy: A systematic and updated review","volume":"25","author":"Ara","year":"2024","journal-title":"AAPS Pharm. Sci. Tech."},{"issue":"3\u2013s","key":"10.1016\/j.ijbiomac.2025.144497_bb0230","doi-asserted-by":"crossref","first-page":"758","DOI":"10.22270\/jddt.v9i3-s.2750","article-title":"Nanostructured lipid carriers: a platform to lipophilic drug for oral bioavailability enhancement","volume":"9","author":"Patil","year":"2019","journal-title":"J. Drug Deliv. Ther."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.144497_bb0235","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1177\/08853282211034625","article-title":"Magnetic nanostructured lipid carrier for dual triggered curcumin delivery: preparation, characterization and toxicity evaluation on isolated rat liver mitochondria","volume":"36","author":"Yoozbashi","year":"2022","journal-title":"J. Biomater. Appl."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.144497_bb0240","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2174\/1567201816666191029121036","article-title":"In vivo antiplasmodial activity of curcumin-loaded nanostructured lipid carriers","volume":"16","author":"Rashidzadeh","year":"2019","journal-title":"Curr. Drug Deliv."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.144497_bb0245","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s13346-023-01407-7","article-title":"Chitosan-coated nanostructured lipid carriers for effective brain delivery of Tanshinone IIA in Parkinson\u2019s disease: interplay between nuclear factor-kappa \u03b2 and cathepsin B","volume":"14","author":"Hassan","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0250","article-title":"Chitosan coated niosomes for nose-to-brain delivery of clonazepam: formulation, stability and permeability studies","volume":"6","author":"Nerli","year":"2023","journal-title":"Carbohydr. Polym. Technol. Appl."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0255","first-page":"1","article-title":"Intranasal trimethyl chitosan-coated emulsomes containing tizanidine as brain-targeted therapy in spasticity: formulation, optimization, and pharmacokinetic assessment","author":"Elkomy","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0260","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1134\/S1061934815030120","article-title":"A. 1, 2-naphthoquinone-4-sulfonic acid sodium salt as a reagent for spectrophotometric determination of rimantadine and memantine","volume":"70","author":"Muszalska","year":"2015","journal-title":"J. Anal. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.144497_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1752-153X-6-1","article-title":"Novel spectrophotometric method for determination of cinacalcet hydrochloride in its tablets via derivatization with 1, 2-naphthoquinone-4-sulphonate","volume":"6","author":"Darwish","year":"2012","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2009\/810104","article-title":"Selective spectrophotometric and spectrofluorometric methods for the determination of amantadine hydrochloride in capsules and plasma via derivatization with 1, 2-naphthoquinone-4-sulphonate","volume":"2009","author":"Mahmoud","year":"2009","journal-title":"Int. J. Anal. Chem."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2009\/237601","article-title":"Simple spectrophotometric method for determination of paroxetine in tablets using 1, 2-naphthoquinone-4-sulphonate as a chromogenic reagent","volume":"2009","author":"Darwish","year":"2009","journal-title":"Int. J. Anal. Chem."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0280","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.saa.2012.08.024","article-title":"Novel spectrophotometric method for determination of some macrolide antibiotics in pharmaceutical formulations using 1, 2-naphthoquinone-4-sulphonate","volume":"99","author":"Ashour","year":"2012","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.144497_bb0285","first-page":"117","article-title":"Development and validation of assay method of estimation of amantadine hydrochloride by HPLC","volume":"1","author":"Kunjir","year":"2011","journal-title":"Int. J. Discov. Herb. Res."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0290","first-page":"4728","article-title":"Validated UV spectroscopic method for estimation of montelukast sodium","volume":"6","author":"Singh","year":"2015","journal-title":"Int. J. Pharm. Sci. Res."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.144497_bb0295","first-page":"123","article-title":"Implementation of hydrotropic solvents for UV spectrophotometric assessment of esomeprazole-loaded microspheres: greenness evaluation","volume":"14","author":"Nithisha","year":"2024","journal-title":"Asian J. Pharm. Technol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.144497_bb0300","first-page":"258","article-title":"Spectrophotometric determination of atomoxetine hydrochloride from its pharmaceutical dosage forms","volume":"2","author":"Koradia","year":"2009","journal-title":"Asian J. Res. Chem."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.144497_bb0305","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5958\/2231-5713.2019.00042.4","article-title":"Colorimetric estimation of nebivolol hydrochloride in bulk and pharmaceutical dosage form","volume":"9","author":"Ahamed","year":"2019","journal-title":"Asian J. Pharm. Technol."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122295","article-title":"Novel mucoadhesive PLGA-PVM\/MA micro-nanocomposites loaded with felodipine intended for pulmonary administration by nebulization","volume":"628","author":"Isabel","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.144497_bb0315","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/03639045.2019.1576724","article-title":"Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies","volume":"45","author":"Gadhave","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0320","doi-asserted-by":"crossref","first-page":"102179","DOI":"10.1016\/j.jddst.2020.102179","article-title":"Brain targeted delivery of sumatriptan succinate loaded chitosan nanoparticles: preparation, in vitro characterization, and (neuro-) pharmacokinetic evaluations","volume":"61","author":"Masjedi","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0325","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jddst.2016.03.008","article-title":"Intranasal delivery of venlafaxine loaded nanostructured lipid carrier: risk assessment and QbD based optimization","volume":"33","author":"Shah","year":"2016","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0330","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10876-024-02608-x","article-title":"Optimization, characterization and in-vitro cellular uptake of donepezil-loaded NanoCrystVesicles","volume":"35","author":"Dhiman","year":"2024","journal-title":"J. Clust. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.144497_bb0335","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/10717540903431586","article-title":"Preparation and characterization of silybin-loaded nanostructured lipid carriers","volume":"17","author":"Jia","year":"2010","journal-title":"Drug Deliv."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.144497_bb0340","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/10667857.2019.1674522","article-title":"Improved brain pharmacokinetics following intranasal administration of N, N, N-trimethyl chitosan tailored mucoadhesive NLCs","volume":"35","author":"Pardeshi","year":"2020","journal-title":"Mater. Tech."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0345","article-title":"Formulation development and evaluation of rotigotine mucoadhesive nanoemulsion for intranasal delivery","volume":"54","author":"Choudhury","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.144497_bb0350","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/pharmaceutics11080397","article-title":"Short term stability testing of Efavirenz-loaded solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) dispersions","volume":"11","author":"Makoni","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122614","article-title":"Strategic nanocarriers to control neurodegenerative disorders: concept, challenges, and future perspective","volume":"633","author":"Ashique","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"358","key":"10.1016\/j.ijbiomac.2025.144497_bb0360","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jconrel.2023.04.021","article-title":"Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson\u2019s disease","volume":"2023","author":"Saha","year":"2023","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.144497_bb0365","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.neuint.2013.07.002","article-title":"Protective effect of nebivolol on reserpine-induced neurobehavioral and biochemical alterations in rats","volume":"63","author":"Nade","year":"2013","journal-title":"Neurochem. Int."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.144497_bb0370","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.brainresbull.2005.09.019","article-title":"Effects of baclofen on reserpine-induced vacuous chewing movements in mice","volume":"68","author":"Castro","year":"2006","journal-title":"Brain Res. Bull."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.144497_bb0375","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/109662003322233503","article-title":"Effect of Withania somnifera root extract on haloperidol-induced orofacial dyskinesia: possible mechanisms of action","volume":"6","author":"Naidu","year":"2003","journal-title":"J. Med. Food"},{"issue":"Supplement C","key":"10.1016\/j.ijbiomac.2025.144497_bb0380","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.neuropharm.2014.07.012","article-title":"Retracted: neuroprotective and neurotrophic effects of apigenin and luteolin in MPTP induced parkinsonism in mice","volume":"86","author":"Patil","year":"2014","journal-title":"Neuropharmacol"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.144497_bb0385","first-page":"70","article-title":"In-vitro and-vivo antioxidant activities of aqueous extract of Strychnos henningsii Gilg","volume":"4","author":"Oyedemi","year":"2010","journal-title":"Afr. J. Pharm. Pharmacol"},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0390","series-title":"Methods of enzymatic analysis","first-page":"885","article-title":"Catalase","author":"Luck","year":"1971"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.144497_bb0395","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","article-title":"Tissue sulfhydryl groups","volume":"82","author":"Ellman","year":"1959","journal-title":"Arch. Biochem. Biophys."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.144497_bb0400","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.144497_bb0405","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0003-9861(78)90479-4","article-title":"Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase","volume":"186","author":"Kono","year":"1978","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0410","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jcis.2017.07.008","article-title":"Effect of surfactant concentration and solidification temperature on the characteristics and stability of nanostructured lipid carrier (NLC) prepared from rambutan (Nephelium lappaceum L.) kernel fat","volume":"505","author":"Witayaudom","year":"2017","journal-title":"J. Colloid Interface Sci."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.144497_bb0415","first-page":"1912","article-title":"Development, optimization and evaluation of surfactant-based pulmonary nanolipid carrier system of paclitaxel for the management of drug resistance lung cancer using box-Behnken design","volume":"23","author":"Kaur","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0420","doi-asserted-by":"crossref","first-page":"120571","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications","volume":"601","author":"Guimar\u00e3es","year":"2021","journal-title":"Int. J. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0425","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejpb.2018.10.017","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release","volume":"133","author":"Gordillo-Galeano","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0430","article-title":"Preparation, physicochemical and biopharmaceutical characterization of oxcarbazepine-loaded nanostructured lipid carriers as potential antiepileptic devices","volume":"63","author":"Montoto","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0435","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijpharm.2011.03.051","article-title":"Higuchi equation: derivation, applications, use and misuse","volume":"418","author":"Siepmann","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.144497_bb0440","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1208\/pt0801016","article-title":"Degradation kinetics and mechanism of RH1, a new anti-tumor agent: a technical note","volume":"8","author":"Jain","year":"2007","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0445","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.gene.2018.04.010","article-title":"Differential expression of miR-34a, miR-141, and miR-9 in MPP+-treated differentiated PC12 cells as a model of Parkinson\u2019s disease","volume":"662","author":"Delavar","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtemb.2023.127208","article-title":"Integrated insight into the molecular mechanisms of selenium-modulated, MPP+-induced cytotoxicity in a Parkinson\u2019s disease model","volume":"79","author":"Liu","year":"2023","journal-title":"J. Trace Elem. Med. Biol."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0455","article-title":"Selenium nanoparticles decorated with polysaccharides from *Sargassum fusiforme* protects against 6-OHDA-induced neurotoxicity in PC12 cells and rat model of Parkinson\u2019s disease","volume":"59","author":"Zhao","year":"2024","journal-title":"Nanomedicine (London)"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.144497_bb0460","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10020228","article-title":"Crustacean waste-derived chitosan: antioxidant properties and future perspective","volume":"10","author":"Muthu","year":"2021","journal-title":"Antioxid"},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0465","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11051-023-05880-6","article-title":"Brain targeting of drugs via intranasal route in conjunction with nanoparticle-based systems: an updated review","volume":"25","author":"Furquan","year":"2023","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0470","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10876-023-02528-2","article-title":"Systematic designing and optimization of polymeric nanoparticles using central composite design: A novel approach for nose-to-brain delivery of donepezil hydrochloride","volume":"35","author":"Garg","year":"2024","journal-title":"J. Clust. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.144497_bb0475","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1055\/a-1924-7818","article-title":"Development and evaluation of topical Ethosomal gel for fungal infections","volume":"73","author":"Gupta","year":"2023","journal-title":"Drug Res."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.144497_bb0480","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1055\/s-0033-1351257","article-title":"Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson\u2019s disease: results from an open-label study","volume":"63","author":"Takanashi","year":"2013","journal-title":"Drug Res."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0485","article-title":"Development, screening and optimization of rosuvastatin loaded nanostructured lipid carriers for improved therapeutic efficacy","author":"El Sayed Gamal","year":"2024","journal-title":"Univers. J. Pharma. Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.144497_bb0490","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00604-024-06250-2","article-title":"In vitro drug screening models derived from different PC12 cell lines for exploring Parkinson\u2019s disease based on electrochemical signals of catecholamine neurotransmitters","volume":"191","author":"Zhong","year":"2024","journal-title":"Microchim. Acta"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.144497_bb0495","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s11064-021-03488-7","article-title":"Lipid-based nanocarriers via nose-to-brain pathway for central nervous system disorders","volume":"47","author":"Nguyen","year":"2022","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0500","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400343","article-title":"Nanocarriers for the treatment of glioblastoma multiforme: A succinct review of conventional and repositioned drugs in the last decade","author":"Bayoumi","year":"2024","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.144497_bb0505","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s13346-024-01635-5","article-title":"Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines","volume":"14","author":"Borrajo","year":"2024","journal-title":"Drug Deliv. Transl. Res."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025050494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025050494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T07:57:27Z","timestamp":1749369447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025050494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":101,"alternative-id":["S0141813025050494"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.144497","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chitosan-coated nanostructured lipid carriers of amantadine for nose-to-brain delivery: formulation optimization, in vitro-ex vivo characterization, and in vivo anti-parkinsonism assessment","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.144497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"144497"}}